Prostate targeting ligands based on N-acetylated α-linked acidic dipeptidase

Biochemical and Biophysical Research Communications

Volumn 307, Issue 1, 2003, Pages 8-14

  Tang, Hailun ^a   Brown, Mark ^a   Ye, Yunpeng ^b   Huang, Guofeng ^b   Zhang, Yihua ^b   Wang, Yuesheng ^b   Zhai, Haixiao ^b   Chen, Xiaohui ^b   Shen, Tsung Ying ^b   Tenniswood, Martin ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Glutamate carboxypeptidase; Metastasis; NAALADase; Prostate cancer; PSMA

Indexed keywords

DIPEPTIDASE; LIGAND; N ACETYLASPARTYLGLUTAMIC ACID; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOACTIVE IODINE;

ACETYLATION; ACIDITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL KINETICS; CELL SURFACE; CYTOTOXICITY; DRUG SYNTHESIS; ENZYME ACTIVITY; FLUORESCENCE; HUMAN; HUMAN CELL; HYDROLYSIS; IC 50; MALE; MEMBRANE BINDING; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN TARGETING;

EID: 0037711901     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01119-7     Document Type: Article

References (27)

1. Landis S.H., Murray T., Boldon S., Wingo P.A. Cancer statistics. CA Cancer J. Clin. 49:1999;8-31.
2. Dennis L.K., Resnick M.I. Analysis of recent trends in prostate cancer incidence and mortality. Prostate. 42:2000;247-252.
3. Sardi I., Moretti S., Ponchietti R., Arrigucci S., Guazzelli R., Montali E. The Role of the detection of hematogenous micrometastasis in prostate adenocarcinoma and malignant melanoma by RT-PCR. Int. J. Mol. Med. 3:1999;417-419.
4. Wang S., Diamond D.L., Hass G.M., Sokoloff R., Vessella R.L. Identification of prostate specific antigen (PSMA) as the target of monoclonal antibody 107-1A4 by protein chip; array, surface-enhanced laser desorption/ionization (SELDI) technology. Int. J. Cancer. 92:2001;871-876.
5. Potter S.R., Mangold L.A., Shue M.J., Taylor D.C., Lecksell K.L., Epstein J.I., Walsh P.C., Partin A.W. Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative lymph nodes at radical prostatectomy. Cancer. 89:2000;2577-2586.
6. Holmes E.H., Greene T.G., Tino W.T., Boynton A.L., Aldape H.C., Misrock S., Murphy G.P. Analysis of glycosylation of prostate-specific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors and serum from prostate cancer patients. Prostate. 7:1996;25-29.
7. Silver D.A., Pellicer I., Fair W.R., Heston W.D., Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3:1997;81-85.
8. Gregorakis A.K., Holmes E.H., Murphy G.P. Prostate-specific membrane antigen: current and future utility. Semin. Urol. Oncol. 16:1998;2-12.
9. Chang S.S., O'Keefe D.S., Bacich D.J., Reuter V.E., Heston W.D., Gaudin P.B. Prostate-specific membrane antigen is produced in tumor-associated neo-vasculature. Clin. Cancer Res. 5:1999;2674-2681.
10. Murphy G., Ragde H., Kenny G., Barren R., Erickson S., Tjoa B., Boynton A.L., Holmes E., Gilbaugh J., Douglas T. Comparison of prostate-specific membrane antigen and prostate specific antigen levels in prostate cancer patients. Anticancer Res. 15:1995;1473-1479.
11. Murphy G.P., Maquire R.T., Rogers B., Partin A.W., Nelp W.B., Troychak M.J., Ragde H., Kenny G.M., Barren R.J., Bowes V.A., Gregorakis A.K., Holmes E.H., Boynton A.L. Comparison of serum PSMA, PSA levels with results of Cytogen-35ProstaScint scanning in prostatic cancer patients. Prostate. 33:1997;281-285.
12. Rosenthal S.A., Haseman M.K., Polascik T.J. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech. Urol. 7:2001;27-27.
13. Lange P. ProstaScint scan for staging prostate cancer. Urology. 57:2001;399-401.
14. Tiffany C.W., Lapidus R.G., Merion A., Calvin D.C., Slusher B. Characterization of the enzymatic activity of PSM: comparison with brain NAALADase. Prostate. 39:1999;28-35.
15. Troyer J.K., Beckett M.L., Wright G.L. Detection and characterization of the prostate specific membrane antigen (PSMA) in tissue extracts and body fluids. Prostate. 30:1997;232-242.
16. ′ protein in the LNCaP prostatic carcinoma cell line Cancer Res. 58:1998;4787-4789.
17. Su S.L., Huang I.P., Fair W.R., Powell C.T., Heston W.D. Alternatively spliced variants of prostate specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res. 55:1995;1441-1443.
18. Weissensteiner T. Prostate cancer cells show a nearly 100-fold increase in the expression of the longer of two alternatively spliced mRNAs of the prostate-specific membrane antigen (PSM). Nucleic Acids Res. 26:1998;687.
19. O'Keefe D.S., Su S.L., Bacich D.J., Horiguchi Y., Luo Y., Powell C.T., Zandvliet D., Russell P.J., Molloy P.L., Nowak N.J., Shows T.B., Mullins C., VonderHaar R.A., Fair W.R., Heston W.D. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim. Biophys. Acta. 1443:1998;113-127.
20. Maraj B.H., Leek J.P., Karayi M., Ali M., Lench N.J., Markham A.F. Detailed genetic mapping around a putative prostate specific membrane antigen locus on human chromosome 11p12.2. Cytogenet. Cell. Genet. 81:1998;3-9.
21. Jackson P.F., Cole D.C., Slusher B.S., Stetz S.L., Ross L.E., Donzanti B.A., Trainor D.A. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated α-linked acidic dipeptidase. J. Med. Chem. 39:1996;619-622.
22. Serval V., Barbeito A., Pittaluga A., Cheramy A., Lavielle S., Glowinski J. Competitive inhibition of N-acetylated-α-linked acidic dipeptidase activity by N-acetyl-L-aspartyl-β-linked L-glutamate. J. Neurochem. 55:1990;39-46.
23. Slusher B.S., Robinson M.B., Tsai G., Simmons M.L., Richards S.S., Coyle J.T. Rat brain N-acetylated α-linked acidic dipeptidase activity. J. Biol. Chem. 265:1990;21297-21301.
24. Slusher B.S., Vornov J.J., Thomas A.G., Hurn P.D., Harukuni I., Bhardwaj A., Traystman R.J., Robinson M.B., Britton P., Lu X.C., Tortella F.C., Wozniak K.M., Yudkoff M., Potter B.M., Jackson P.F. Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 5:1999;1396-1402.
25. Murphy G.P., Kenny G.M., Radge H., Wolfert R.L., Boynton A.L., Holmes E.H., Misrock S.L., Bartsch G., Klocker H., Pointner J., Reissigl A., McLeod D.G., Douglas T., Morgan T., Gilbaugh J. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology. 51:1998;89-97.
26. Murphy G.P., Elgamal A.-A.A., Troychak M.J., Kenny G.M. Followup ProstaScint scans verify the detection of occult soft-tissue recurrence after failure of primary prostate cancer therapy. Prostate. 42:2000;315-317.
27. Noss K.R., Singal R., Grimes S.R. Methylation state of the prostate specific membrane antigen CpG island in prostate cancer cell lines. Anticancer Res. 22:2002;1505-1511.